REGN

Regeneron Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

542.520

-7.48(-1.360%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

550.885

Open

550.000

VWAP

543.43

Vol

1.31M

Mkt Cap

58.57B

Low

541.500

Amount

710.73M

EV/EBITDA(TTM)

11.51

Total Shares

110.19M

52.93B

EV/OCF(TTM)

13.39

P/S(TTM)

4.39

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

3.57B

-5.78%

9.361

-22.44%

3.46B

-7.08%

9.227

-25.95%

3.31B

-6.72%

8.510

-26.39%

Estimates Revision

The market is revising Downward the revenue expectations for Regeneron Pharmaceuticals, Inc. (REGN) for FY2025, with the revenue forecasts being adjusted by -6.4% over the past three months. During the same period, the stock price has changed by -3.38%.

Revenue Estimates for FY2025

Revise Downward

-6.4%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-13.09%

In Past 3 Month

Stock Price

Go Down

-3.38%

In Past 3 Month

24 Analyst Rating

34.94% Upside

Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 732.10 USD with a low forecast of 535.00 USD and a high forecast of 900.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Buy

6 Hold

1 Sell

Moderate Buy

34.94% Upside

Current: 542.520

Low

535.00

Averages

732.10

High

900.00

34.94% Upside

Current: 542.520

Low

535.00

Averages

732.10

High

900.00

UBS

Trung Huynh

Neutral

maintain

$560 -> $584

2025-07-11

Reason

UBS

Trung Huynh

Price Target

$560 -> $584

2025-07-11

maintain

Neutral

Reason

UBS analyst Trung Huynh raised the firm's price target on Regeneron to $584 from $560 and keeps a Neutral rating on the shares. UBS is 2% above consensus for Q2 financials, driven by positive expectations for the Eylea franchise, the analyst tells investors in a research note. The firm views current valuation as fairly reflecting the mixed risk/rewards in near-term.

Morgan Stanley

Terence Flynn

Overweight

maintain

$755 -> $754

2025-07-10

Reason

Morgan Stanley

Terence Flynn

Price Target

$755 -> $754

2025-07-10

maintain

Overweight

Reason

Morgan Stanley analyst Terence Flynn lowered the firm's price target on Regeneron to $754 from $755 and keeps an Overweight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.

Argus

Buy

Hold

downgrade

2025-06-30

Reason

Argus

Price Target

2025-06-30

downgrade

Buy

Hold

Reason

Argus downgraded Regeneron to Hold from Buy.

JPMorgan

Overweight

downgrade

$950 -> $800

2025-06-09

Reason

JPMorgan

Price Target

$950 -> $800

2025-06-09

downgrade

Overweight

Reason

UBS

Neutral

downgrade

$633 -> $560

2025-06-05

Reason

UBS

Price Target

$633 -> $560

2025-06-05

downgrade

Neutral

Reason

UBS lowered the firm's price target on Regeneron to $560 from $633 and keeps a Neutral rating on the shares. Regeneron recently announced several corporate and pipeline updates, including the acquisition of 23andMe for $256M, topline readout from the itepekimab Phase 3 AERIFY-1/2 trials in COPD, the interim analysis from the Phase 2 COURAGE study, and the licensing of ex-China rights for a Phase 3 GLP-1/GIP RA asset from Hansoh, the analyst tells investors in a research note. The Eylea franchise weakness remains a key overhang for the firm's near-term thesis.

Morgan Stanley

Terence Flynn

Overweight

downgrade

$958 -> $755

2025-06-02

Reason

Morgan Stanley

Terence Flynn

Price Target

$958 -> $755

2025-06-02

downgrade

Overweight

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Regeneron Pharmaceuticals Inc (REGN.O) is 15.20, compared to its 5-year average forward P/E of 16.34. For a more detailed relative valuation and DCF analysis to assess Regeneron Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

16.34

Current PE

15.20

Overvalued PE

20.33

Undervalued PE

12.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

11.57

Current EV/EBITDA

9.95

Overvalued EV/EBITDA

14.75

Undervalued EV/EBITDA

8.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

5.82

Current PS

4.27

Overvalued PS

7.00

Undervalued PS

4.63